Ensuring that the diagnosis of tuberculosis accelerates progress towards the millennium development goals

European Respiratory Journal

Volumn 44, Issue 1, 2014, Pages 1-4

  Hanson, Christy ^a   Sotgiu, Giovanni ^b   Loddenkemper, Robert ^c  

^a MACALESTER COLLEGE   (United States)

^b UNIVERSITY OF SASSARI   (Italy)

^c German Central Committee Against Tuberculosis   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; DIAGNOSTIC PROCEDURE; EVIDENCE BASED MEDICINE; FLUORESCENT LIGHT EMITTING DIODE MICROSCOPY; FUNDING; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE PLANNING; HUMAN; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; MEDICAL LITERATURE; MOLECULAR LINE PROBE ASSAY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; NUCLEIC ACID AMPLIFICATION; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLISHING; REVIEW; SENSITIVITY ANALYSIS; SERODIAGNOSIS; SPUTUM EXAMINATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; ANTIBIOTIC RESISTANCE; ECONOMICS; GENETICS; MICROBIOLOGY; MOLECULAR DIAGNOSIS; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

DRUG RESISTANCE, BACTERIAL; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84903823335     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00028514     Document Type: Review

References (26)

1. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva, WHO, 2013.
2. United Nations. Millennium Development Goals Report. New York, United Nations, 2011.
3. Keeler E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 2006; 444: Suppl. 1, 49-57.
4. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379: 1902-1913.
5. Pai M, Palamountain KM. New tuberculosis technologies: challenges for retooling and scale-up. Int J Tuberc Lung Dis 2012; 16: 1281-1290.
6. Drobniewski F, Nikolayevskyy V, Balabanova Y, et al. Diagnosis of tuberculosis and drug resistance: what can new tools bring us. Int J Tuberc Lung Dis 2012; 16: 860-870.
7. Peter JG, Theron G, van Zyl-Smit R, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012; 40: 1211-1220.
8. Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 2012; 367: 931-936.
9. World Health Organization. Policy Framework for Implementing TB Diagnostics. Geneva, WHO, 2011.
10. World Health Organization. Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement. WHO/HTM/TB/2011.5. Geneva, WHO, 2011.
11. World Health Organization. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middleincome countries: policy statement. WHO/HTM/TB/2011.18. Geneva, WHO, 2011.
12. Trébucq A, Enarson DA, Chiang CY, et al. Xpert1 MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how. Int J Tuberc Lung Dis 2011; 15: 1567-1572.
13. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013; 42: 252-271.
14. Pantoja A, Fitzpatrick C, Vassall A, et al. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J 2013; 42: 708-720.
15. World Health Organization. Policy Statement: Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. WHO/ HTM/TB/2011.4. Geneva, WHO, 2011.
16. World Health Organization. Rapid Implementation of the Xpert MTB/RIF Diagnostic Test. Technical and Operational How-to Practical Considerations. WHO/HTM/TB/2011.2. Geneva, WHO, 2011.
17. Floyd K, Hutubessy R, Kliiman K, et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J 2012; 40: 133-142.
18. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging concensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.
19. World Health Organization, Stop TB Partnership. Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics. Geneva, WHO, 2009.
20. Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 2012; 7: e36966.
21. Espinal MA, Dye C, Raviglione M, et al. Rational DOTS plus for the control of MDR-TB. Int J Tuberc Lung Dis 1999; 3: 561-563.
22. Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol 2008; 65: 795-796.
23. Albanna AS, Smith BM, Cowan D, et al. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J 2013; 42: 721-732.
24. Barnard M, Warren R, Van Pittius NG, et al. GenoType MTBDRsl Line Probe Assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med 2012; 186: 1298-1305.
25. Pai M, Minion J, Steingart K, et al. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 2010; 16: 271-284.
26. Caminero JA, Matteelli A, Loddenkemper R. Tuberculosis: are we making it incurable. Eur Respir J 2013; 42: 5-8.